PVCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PVCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Provectus Biopharmaceuticals's Net Income for the three months ended in Dec. 2024 was $-2.40 Mil. Provectus Biopharmaceuticals's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Provectus Biopharmaceuticals's net margin for the quarter that ended in Dec. 2024 was 0.00%.
The historical rank and industry rank for Provectus Biopharmaceuticals's Net Margin % or its related term are showing as below:
The historical data trend for Provectus Biopharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provectus Biopharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Net Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Provectus Biopharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Net Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Provectus Biopharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Provectus Biopharmaceuticals's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Provectus Biopharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | -4.762 | / | 0 | |
= | % |
Provectus Biopharmaceuticals's Net Margin for the quarter that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | -2.397 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provectus Biopharmaceuticals (OTCPK:PVCT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey Allen Morris | 10 percent owner | 1729 TRIANGLE PARK DR., MARYVILLE TN 37801 |
Webster Bailey | director | 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932 |
Heather Raines | officer: Chief Financial Officer | 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932 |
Edward Pershing | director | 2220 SOUTHERLAND AVE, KNOXVILLE TN 37919 |
John Iii Lacy | director | 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932 |
John R Glass | officer: See Remarks | 7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931 |
Bruce Horowitz | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Dominic Rodrigues | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Peter R Culpepper | officer: Interim CEO, CFO, COO | 7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931 |
Eric Phd Wachter | director, officer: Chief Technology Officer | PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Jan Koe | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Smith Alfred E. Iv | director | 191 MAIN STREET, NEW CANAAN CT 06840 |
Kelly M Mcmasters | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Donald E Adams | 10 percent owner | 370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401 |
Timothy Phd Scott | director, 10 percent owner, officer: President | PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
From GuruFocus
By Marketwired • 04-16-2024
By PurpleRose PurpleRose • 08-24-2022
By Marketwired • 06-13-2024
By Marketwired • 04-18-2024
By Stock market mentor Stock market mentor • 01-09-2023
By PurpleRose PurpleRose • 07-10-2022
By Marketwired • 08-07-2023
By Marketwired • 06-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.